Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | STAT5B | P51692 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862225 | 0.90 | KMT2A (0.43) | F2ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL1858551 | 0.84 | MAPT (0.41) | TP53THRBALDH1A1POLBLMNA | |
| SCHEMBL1856336 | 0.82 | KMT2A (0.48) | TP53THRBALDH1A1POLBLMNA | |
| SCHEMBL1860642 | 0.81 | CA12 (0.38) | TP53THRBF2ALDH1A1POLB | |
| SCHEMBL1860213 | 0.80 | ATM (0.38) | F2ALDH1A1LMNAKMT2A | |
| SCHEMBL1858294 | 0.76 | KMT2A (0.47) | TP53THRBF2ALDH1A1LMNA | |
| SCHEMBL2968367 | 0.76 | MMP2 (0.41) | TP53F2LMNAKDM4ESTAT5B | |
| SCHEMBL2377556 | 0.75 | F2 (0.38) | F2ALDH1A1LMNAKDM4ESTAT5B | |
| SCHEMBL1860371 | 0.74 | STAT5B (0.41) | TP53ALDH1A1POLBHCRTR2STAT5B | |
| SCHEMBL9452031 | 0.74 | LMNA (0.42) | TP53F2LMNAKDM4ESTAT5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | TP53 143/4885THRB 1416/4885F2 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.